Our findings actually echo several previous reports focusing on adopting BET inhibitors and PI3K-targeting agents in the treatment of cancers (including DLBCL) [41,42,43], although the inter-collaborative activity between them differs across studies. This evidence concerns the gene DNER and diffuse large B-cell lymphoma.